Korean medication algorithm for bipolar disorder 2014: Comparisons with other treatment guidelines

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 1561-1571

  Jeong, Jong Hyun ^a   Lee, Jeong Goo ^b,c   Kim, Moon Doo ^d   Sohn, Inki ^e   Shim, Se Hoon ^f   Wwang, Hee Ryung ^a   Woo, Young Sup ^a   Jon, Duk In ^g   Seo, Jeong Seok ^h   Shin, Young Chul ⁱ   Min, Kyung Joon ^j   Yoon, Bo Hyun ^k   Bahk, Wwon Myong ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Graduate School of InjeUniversity   (South Korea)

^d Jeju National University   (South Korea)

^e Keyo Hospital   (South Korea)

^f Soonchunhyang University College of Medicine   (South Korea)

^g Hallym University College of Medicine   (South Korea)

^h Konkuk University Hospital   (South Korea)

ⁱ Sungkyunkwan University School of Medicine   (South Korea)

^j Chung Ang University   (South Korea)

^k Naju National Hospital   (South Korea)

more..

Author keywords

Bipolar disorder; Guideline comparison; KMAP 2014; Pharmacotherapy; Treatment algorithm

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BLONANSERIN; CLOZAPINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ALGORITHM; BIPOLAR DISORDER; BIPOLAR II DISORDER; CLINICAL DECISION MAKING; DEPRESSION; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; HUMAN; HYPOMANIA; MAINTENANCE THERAPY; MANIA; PRACTICE GUIDELINE; QUESTIONNAIRE; REVIEW; TREATMENT INDICATION;

EID: 84936854388     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S86552     Document Type: Review

References (51)

1. Evidence Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268(17):2420–2425
2. American Psychiatric Association. Practice guideline for eating disorders. American Psychiatric Association. Am J Psychiatry. 1993;150(2): 212–228
3. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. Am J Psychiatry. 1994;151(12 suppl):1–36
4. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad Med. 2000:1–104
5. Kahn DA, Sachs GS, Printz DJ, Carpenter D, Docherty JP, Ross R. Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines. J Psychiatr Pract. 2000;6(4):197–211
6. Suppes T, Dennehy EB, Hirschfeld RM, et al; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7):870–886
7. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17(2):149–173. discussion 147
8. The Executive Committee of Korean Bipolar Medication Algorithm Project for Bipolar Disorder. The Korean Medication Guideline for Bipolar Disorder 2002. Seoul Korea: Jungang Moonwhasa; 2002
9. Jon DI, Bahk WM, Yoon BH, et al. Algorithm-driven treatment for bipolar disorder in Korea: clinical feasibility, efficacy, and safety. Int J Psychiatry Clin Pract. 2009;13(2):122–129
10. Jon DI, Bahk WM, Yoon BH, et al. Revised Korean medication algorithm for bipolar disorder. World J Biol Psychiatry. 2009;10(4 pt 3): 846–855
11. Shin YC, Min KJ, Yoon BH, et al. Korean medication algorithm for bipolar disorder: second revision. Asia Pac Psychiatry. 2013; 5(4):301–308
12. Woo YS, Lee JG, Jeong JH, et al. Korean medication algorithm project for bipolar disorder: third revision. Neuropsychiatr Dis Treat. 2015;11:493–506
13. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346–388
14. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44
15. National Collaborating Centre for Mental Health. Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. Leicester UK: The British Psychological Society; The Royal College of Psychiatrists; 2014
16. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85–116
17. Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force On Treatment Guidelines For Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81–109
18. Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219
19. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159 (4 suppl):1–50
20. Sharma V, Yatham LN, Haslam DR, et al. Continuation and prophylactic treatment of bipolar disorder. Can J Psychiatry. 1997;42(suppl 2): 92S–100S
21. Yatham LN, Kennedy SH, O’Donovan C, et al; Canadian Network for Mood and Anxiety Treatments. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(suppl 3):5–69
22. Yatham LN, Kennedy SH, O’Donovan C, et al; Guidelines Group, CANMAT. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8(6):721–739
23. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–255
24. National Collaborating Centre for Mental Health (UK). Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. Leicester UK: The British Psychological Society; The Royal College of Psychiatrists; 2006
25. Grunze H, Kasper S, Goodwin G, et al; World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry. 2002;3(3): 115–124
26. Grunze H, Kasper S, Goodwin G, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part II: treatment of mania. World J Biol Psychiatry. 2003;4(1):5–13
27. Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry. 2004;5(3):120–135
28. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010; 13(1):5–14
29. Selle V, Schalkwijk S, Vazquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47(2):43–52
30. Fountoulakis KN, Kontis D, Gonda X, Yatham LN. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord. 2013;15(2):115–137
31. Vieta E, Valenti M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013; 27(7):515–529
32. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60(2):79–88
33. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351–1360
34. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006; 26(6):600–609
35. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4–9
36. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26–36
37. Calabrese JR, Shelton MD, Bowden CL, et al. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry. 2001;62(suppl 14): 34–41
38. Gonzalez-Pinto A, Tohen M, Lalaguna B, et al. Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine. J Clin Psychopharmacol. 2002;22(5):450–454
39. Langosch JM, Drieling T, Biedermann NC, et al. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. J Clin Psychopharmacol. 2008;28(5):555–560
40. Zupancic ML. Role of atypical antipsychotics in rapid cycling bipolar disorder: a review of the literature. Ann Clin Psychiatry. 2011; 23(2):141–149
41. Muzina DJ, Momah C, Eudicone JM, et al. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract. 2008;62(5): 679–687
42. Buoli M, Serati M, Altamura AC. Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review. J Affect Disord. 2014; 15(2–154):12–18
43. de Bartolomeis A, Perugi G. Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance. Expert Opin Pharmacother. 2012;13(14): 2027–2036
44. Gitlin M, Frye MA. Maintenance therapies in bipolar disorders. Bipolar Disord. 2012;14(suppl 2):51–65
45. Salvi V, Cat Berro A, Bechon E, Bogetto F, Maina G. Litio e anticonvulsivanti nel trattamento della mania e nella profilassi delle ricorrenze [Lithium and anticonvulsants in the treatment of mania and in the prophylaxis of recurrences]. Riv Psichiatr. 2011;46(3):172–181. Italian
46. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010;68(2):156–162
47. Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009;11(8):827–839
48. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163(2):247–256
49. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162(7): 1281–1290
50. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ. 1997;157(4): 408–416
51. Solberg LI, Brekke ML, Fazio CJ, et al. Lessons from experienced guideline implementers: attend to many factors and use multiple strategies. Jt Comm J Qual Improv. 2000;26(4):171–188.